{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T08:55:43Z","timestamp":1783587343185,"version":"3.55.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gen Intern Med"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1111\/j.1525-1497.2004.30613.x","type":"journal-article","created":{"date-parts":[[2004,4,2]],"date-time":"2004-04-02T15:21:34Z","timestamp":1080919294000},"page":"357-365","source":"Crossref","is-referenced-by-count":70,"title":["Hepatitis C virus infection in san francisco\u2019s HIV-infected urban poor"],"prefix":"10.1007","volume":"19","author":[{"given":"Christopher S.","family":"Hall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin D.","family":"Charlebois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Bangsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"1904357_CR1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"G.M. Lauer","year":"2001","unstructured":"Lauer, G.M. and B.D. Walker, Hepatitis C virus infection. New England Journal of Medicine, 2001. 345(1): p. 41\u201352.","journal-title":"New England Journal of Medicine"},{"key":"1904357_CR2","unstructured":"National Hepatitis C Prevention Strategy: A Comprehensive Strategy for the Prevention and Control of Hepatitis C Virus Infection and its Consequences. 2001, Centers for Disease Control: Atlanta, GA."},{"key":"1904357_CR3","volume-title":"170 million infected worldwide and still no vaccine","author":"C Hepatitis","year":"1998","unstructured":"Hepatitis C: 170 million infected worldwide and still no vaccine. 1998, World Health Organization: Geneva."},{"issue":"Suppl 1","key":"1904357_CR4","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1086\/313842","volume":"30","author":"M.S. Sulkowski","year":"2000","unstructured":"Sulkowski, M.S., et al., Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis, 2000. 30 Suppl 1: p. S77\u201384.","journal-title":"Clin Infect Dis"},{"key":"1904357_CR5","unstructured":"Tedaldi, E., Prevalence and characteristics of HCV co-infection in a community based HIV clinical trials group. in 1st IAS Conference on HIV Pathogenesis and Treatment. 2001. Buenos Aires, Argentina."},{"issue":"6","key":"1904357_CR6","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/339042","volume":"34","author":"K.E. Sherman","year":"2002","unstructured":"Sherman, K.E., et al., Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis, 2002. 34(6): p. 831\u20137.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1904357_CR7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1046\/j.1525-1497.2002.10415.x","volume":"17","author":"A.M. Nyamathi","year":"2002","unstructured":"Nyamathi, A.M., et al., Risk factors for hepatitis C virus infection among homeless adults. J Gen Intern Med, 2002. 17(2): p. 134\u201343.","journal-title":"J Gen Intern Med"},{"issue":"4","key":"1904357_CR8","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2105\/AJPH.92.4.670","volume":"92","author":"K.A. Page-Shafer","year":"2002","unstructured":"Page-Shafer, K.A., et al., Hepatitis C virus infection in young, low-income women: the role of sexually transmitted infection as a potential cofactor for HCV infection. Am J Public Health, 2002. 92(4): p. 670\u20136.","journal-title":"Am J Public Health"},{"issue":"4","key":"1904357_CR9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/00004836-200204000-00021","volume":"34","author":"R.C. Cheung","year":"2002","unstructured":"Cheung, R.C., et al., Viral Hepatitis and Other Infectious Diseases in a Homeless Population. J Clin Gastroenterol, 2002. 34(4): p. 476\u2013480.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"1904357_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2105\/AJPH.91.1.46","volume":"91","author":"J. Lorvick","year":"2001","unstructured":"Lorvick, J., et al., Prevalence and duration of hepatitis C among injection drug users in San Francisco, Calif. Am J Public Health, 2001. 91(1): p. 46\u20137.","journal-title":"Calif. Am J Public Health"},{"issue":"4","key":"1904357_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1300\/J069v20n04_03","volume":"20","author":"A. Rosenblum","year":"2001","unstructured":"Rosenblum, A., et al., Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis, 2001, 20(4): p. 15\u201325.","journal-title":"J Addict Dis"},{"key":"1904357_CR12","unstructured":"Fleming, C.A., et al., Differences among patients infected with HIV and hepatitis C (HCV) versus those infected with HCV alone in an urban hospital clinic. in 39th Annual Meeting of the Infectious Diseases Society of America. 2001. San Francisco, CA."},{"issue":"18","key":"1904357_CR13","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/archinte.161.18.2231","volume":"161","author":"J.P. Leigh","year":"2001","unstructured":"Leigh, J.P., et al., Costs of hepatitis C. Arch Intern Med, 2001. 161(18): p. 2231\u20137.","journal-title":"Arch Intern Med"},{"key":"1904357_CR14","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1001\/archinte.162.22.2545","volume":"162","author":"F.C. Kuehne","year":"2002","unstructured":"Kuehne, F.C., et al., Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med, 2002. 162: p. 2545\u20132556.","journal-title":"Arch Intern Med"},{"issue":"2","key":"1904357_CR15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.290.2.228","volume":"290","author":"J.A. Salomon","year":"2003","unstructured":"Salomon, J.A., et al., Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. Jama, 2003. 290(2): p. 228\u201337.","journal-title":"Jama"},{"issue":"15","key":"1904357_CR16","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1097\/00002030-200110190-00014","volume":"15","author":"L. Serfaty","year":"2001","unstructured":"Serfaty, L., et al., Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. Aids, 2001. 15(15): p. 2011\u20136.","journal-title":"Aids"},{"key":"1904357_CR17","doi-asserted-by":"crossref","unstructured":"Rodriquez, M. and J. Rodriguez, Comparison of the severity of liver disease in HCV-non-HIV-infected patients and HCV-HIV co-infected patients prior to HCV-treatment in an urban area. in Digestive Disease Week. 2001, Atlanta, GA.","DOI":"10.1016\/S0016-5085(08)81821-5"},{"issue":"9244","key":"1904357_CR18","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/S0140-6736(00)03232-3","volume":"356","author":"G. Greub","year":"2000","unstructured":"Greub, G., et al., Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet, 2000. 356(9244): p. 1800\u20135.","journal-title":"Lancet"},{"key":"1904357_CR19","doi-asserted-by":"crossref","unstructured":"Louie, J.K., et al., Trends in Causes of Death in Persons with AIDS in the Era of Highly Active Antiretroviral Therapy, San Francisco: 1994\u20131998. Journal of Infectious Diseases, 2002 (in press).","DOI":"10.1086\/343862"},{"issue":"2","key":"1904357_CR20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1086\/321819","volume":"33","author":"H.K. Monga","year":"2001","unstructured":"Monga, H.K., et al., Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis, 2001. 33(2): p. 240\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1904357_CR21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","volume":"32","author":"I. Bica","year":"2001","unstructured":"Bica, I., et al., Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis, 2001. 32(3): p. 492\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1904357_CR22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/00042560-200201010-00005","volume":"29","author":"A. Aceti","year":"2002","unstructured":"Aceti, A., et al., Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr, 2002. 29(1): p. 41\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1904357_CR23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","volume":"35","author":"M.S. Sulkowski","year":"2002","unstructured":"Sulkowski, M.S., et al., Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology, 2002. 35(1): p. 182\u20139.","journal-title":"Hepatology"},{"issue":"9286","key":"1904357_CR24","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"M.P. Manns","year":"2001","unstructured":"Manns, M.P., et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 2001. 358(9286): p. 958\u201365.","journal-title":"Lancet"},{"key":"1904357_CR25","unstructured":"Chung, R., A Randomized, Controlled Trial of Pegylated Interferon alfa-2a with Ribavirin vs Interferon alfa-2a with Ribavirin for the Treatment of Chronic HCV in HIV Co-Infection: ACTG A5071. in 9th Conference on Retroviruses and Opportunistic Infections. 2002. Seattle, WA."},{"issue":"2","key":"1904357_CR26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jama.285.2.200","volume":"285","author":"M.B. Kushel","year":"2001","unstructured":"Kushel, M.B., E. Vittinghoff, and J.S. Haas, Factors associated with the health care utilization of homeless persons. Jama, 2001. 285(2): p. 200\u20136.","journal-title":"Jama"},{"issue":"5","key":"1904357_CR27","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1056\/NEJM199408043310506","volume":"331","author":"J.R. Hibbs","year":"1994","unstructured":"Hibbs, J.R., et al., Mortality in a cohort of homeless adults in Philadelphia. N Engl J Med, 1994. 331(5): p. 304\u20139.","journal-title":"N Engl J Med"},{"key":"1904357_CR28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev.publhealth.21.1.473","volume":"21","author":"N. Freudenberg","year":"2000","unstructured":"Freudenberg, N., Health promotion in the city: a review of current practice and future prospects in the United States. Annu Rev Public Health, 2000. 21: p. 473\u2013503.","journal-title":"Annu Rev Public Health"},{"issue":"11","key":"1904357_CR29","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM199403173301107","volume":"330","author":"R.D. Moore","year":"1994","unstructured":"Moore, R.D., et al., Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med, 1994. 330(11): p. 763\u20138.","journal-title":"N Engl J Med"},{"issue":"8","key":"1904357_CR30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7326\/0003-4819-118-8-199304150-00004","volume":"118","author":"P.A. Johnson","year":"1993","unstructured":"Johnson, P.A., et al., Effect of race on the presentation and management of patients with acute chest pain. Ann Intern Med, 1993. 118(8): p. 593\u2013601.","journal-title":"Ann Intern Med"},{"issue":"12","key":"1904357_CR31","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2105\/AJPH.76.12.1446","volume":"76","author":"C. Maynard","year":"1986","unstructured":"Maynard, C., et al., Blacks in the coronary artery surgery study (CASS): race and clinical decision making. Am J Public Health, 1986. 76(12): p. 1446\u20138.","journal-title":"Am J Public Health"},{"issue":"12","key":"1904357_CR32","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.1993.03500120075029","volume":"269","author":"K.H. Todd","year":"1993","unstructured":"Todd, K.H., N. Samaroo, and J.R. Hoffman, Ethnicity as a risk factor for inadequate emergency department analgesia. Jama, 1993. 269(12): p. 1537\u20139.","journal-title":"Jama"},{"issue":"3","key":"1904357_CR33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1001\/jama.1989.03420030077033","volume":"261","author":"R.D. Moore","year":"1989","unstructured":"Moore, R.D., et al., Prevalence, detection, and treatment of alcoholism in hospitalized patients. Jama, 1989. 261(3): p. 403\u20137.","journal-title":"Jama"},{"issue":"11","key":"1904357_CR34","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jama.1992.03490110072032","volume":"268","author":"N.R. Powe","year":"1992","unstructured":"Powe, N.R., et al., Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval. Jama, 1992. 268(11): p. 1434\u201340.","journal-title":"Jama"},{"issue":"10","key":"1904357_CR35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/00005650-198910000-00005","volume":"27","author":"P. Diehr","year":"1989","unstructured":"Diehr, P., et al., Treatment modality and quality differences for black and white breast- cancer patients treated in community hospitals. Med Care, 1989. 27(10): p. 942\u201358.","journal-title":"Med Care"},{"key":"1904357_CR36","unstructured":"Robertson, M., et al., HIV seroprevalence and risk factors in a representative sample of homeless and marginally housed adults in San Francisco. AJPH, 2003. in press."},{"issue":"12","key":"1904357_CR37","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/archpsyc.1988.01800360033005","volume":"45","author":"P. Koegel","year":"1988","unstructured":"Koegel, P., M.A. Burnam, and R.K. Farr, The prevalence of specific psychiatric disorders among homeless individuals in the inner city of Los Angeles. Arch Gen Psychiatry, 1988. 45(12): p. 1085\u201392.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1904357_CR38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jama.1994.03520060055032","volume":"272","author":"A.R. Zolopa","year":"1994","unstructured":"Zolopa, A.R., et al., HIV and tuberculosis infection in San Francisco\u2019s homeless adults. Prevalence and risk factors in a representative sample. Jama, 1994. 272(6): p. 455\u201361.","journal-title":"Jama"},{"key":"1904357_CR39","volume-title":"Beck Depression Inventory (BDI-II) Manual","author":"A.T. Beck","year":"1996","unstructured":"Beck, A.T., R.A. Steer and G.K. Brown, Beck Depression Inventory (BDI-II) Manual. 1996, The Psychological Corporation: San Antonio, Texas, U.S.A."},{"issue":"4","key":"1904357_CR40","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00002030-200003100-00008","volume":"14","author":"D.R. Bangsberg","year":"2000","unstructured":"Bangsberg, D.R., et al., Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. Aids, 2000. 14(4): p. 357\u201366.","journal-title":"Aids"},{"issue":"1","key":"1904357_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/jhep.2001.25759","volume":"34","author":"J.A. Hahn","year":"2001","unstructured":"Hahn, J.A., et al., Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology, 2001. 34(1): p. 180\u20137.","journal-title":"Hepatology"},{"issue":"7","key":"1904357_CR42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1093\/aje\/155.7.645","volume":"155","author":"L.E. Thorpe","year":"2002","unstructured":"Thorpe, L.E., et al., Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol, 2002. 155(7): p. 645\u201353.","journal-title":"Am J Epidemiol"},{"issue":"Suppl 1","key":"1904357_CR43","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/00042560-199802001-00004","volume":"18","author":"R.S. Garfein","year":"1998","unstructured":"Garfein, R.S., et al., Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol, 1998. 18(Suppl 1): p. S11\u20139.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"issue":"12","key":"1904357_CR44","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1128\/JCM.35.12.3274-3277.1997","volume":"35","author":"S.A. Villano","year":"1997","unstructured":"Villano, S.A., et al., Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol, 1997. 35(12): p. 3274\u20137.","journal-title":"J Clin Microbiol"},{"key":"1904357_CR45","unstructured":"Fleming, C.A., et al., Experience of an urban hospital referral clinic for evaluation of patients co-infected with HIV and hepatitis C virus (HCV). in 39th Annual Meeting of the Infectious Diseases Society of America. 2001, San Francisco, CA."},{"issue":"1","key":"1904357_CR46","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1572-0241.2002.05439.x","volume":"97","author":"C.H. Cawthorne","year":"2002","unstructured":"Cawthorne, C.H., et al., Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol, 2002. 97(1): p. 149\u201355.","journal-title":"Am J Gastroenterol"},{"issue":"24","key":"1904357_CR47","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1001\/jama.280.24.2088","volume":"280","author":"J.B. Wong","year":"1998","unstructured":"Wong, J.B., et al., Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. Jama, 1998. 280(24): p. 2088\u201393.","journal-title":"Jama"},{"key":"1904357_CR48","unstructured":"Alter, M.J., The epidemiology of hepatitis C. in NIH Consensus Development Conference: Management of Hepatitis C. 1997. Bethesda, MD."},{"issue":"10","key":"1904357_CR49","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/milmed\/166.10.862","volume":"166","author":"K.C. Hyams","year":"2001","unstructured":"Hyams, K.C., et al., Viral hepatitis in the U.S. military: a study of hospitalization records from 1974 to 1999. Mil Med, 2001. 166(10): p. 862\u20135.","journal-title":"Mil Med"},{"issue":"6","key":"1904357_CR50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.280.6.547","volume":"280","author":"S.A. Strathdee","year":"1998","unstructured":"Strathdee, S.A., et al., Barriers to use of free antiretroviral therapy in injection drug users [see comments]. Jama, 1998. 280(6): p. 547\u20139.","journal-title":"Jama"},{"issue":"6","key":"1904357_CR51","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jama.280.6.544","volume":"280","author":"D.D. Celentano","year":"1998","unstructured":"Celentano, D.D., et al., Self-reported antiretroviral therapy in injection drug users. Jama, 1998. 280(6): p. 544\u20136.","journal-title":"Jama"},{"key":"1904357_CR52","unstructured":"Hare, C.B., et al., Viral Hepatitis, Liver Damage, and Antiretroviral Prescribing Patterns in an HIV Community Network. in 9th Conference on Retroviruses and Opportunistic Infections. 2002. Seattle, WA."},{"issue":"8","key":"1904357_CR53","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.2105\/AJPH.92.8.1254","volume":"92","author":"C.C. Pratt","year":"2002","unstructured":"Pratt, C.C., et al., Hepatitis C screening and management practices: a survey of drug treatment and syringe exchange programs in New York City. Am J Public Health, 2002. 92(8): p. 1254\u20136.","journal-title":"Am J Public Health"},{"key":"1904357_CR54","unstructured":"Fraser, M. and J. Buffington, Survey of local health department capacity for hepatitis C and HIV\/AIDS prevention and control programs. in 128th Annual Meeting of the APHA. 2000. Boston, MA."},{"key":"1904357_CR55","volume-title":"Hepatitis C Infection: Epidemiology","author":"T. Aragon","year":"2000","unstructured":"Aragon, T., Hepatitis C Infection: Epidemiology. 2000, San Francisco Department of Public Health: San Francisco, CA."},{"key":"1904357_CR56","unstructured":"Teshale, E.H., et al., Adherence to Guidelines among HIV\/HCV Co-Infected Persons and Providers. in 9th Conference on Retroviruses and Opportunistic Infections. 2002. Seattle, WA."},{"issue":"8","key":"1904357_CR57","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1086\/374049","volume":"36","author":"S.L. Fultz","year":"2003","unstructured":"Fultz, S.L., et al., Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Infect Dis, 2003. 36(8): p. 1039\u201346.","journal-title":"Clin Infect Dis"},{"key":"1904357_CR58","unstructured":"National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C, 2002. 2002."},{"key":"1904357_CR59","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology, 1997. 26(3 Suppl 1): p. 2S\u201310S.","DOI":"10.1002\/hep.510260701"},{"issue":"13","key":"1904357_CR60","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1001\/jama.280.13.1148","volume":"280","author":"G.C. Alexander","year":"1998","unstructured":"Alexander, G.C. and A.R. Sehgal, Barriers to cadaveric renal transplantation among blacks, women, and the poor. JAMA, 1998. 280(13): p. 1148\u201352.","journal-title":"JAMA"},{"issue":"8","key":"1904357_CR61","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJM199902253400806","volume":"340","author":"K.A. Schulman","year":"1999","unstructured":"Schulman, K.A., et al., The effect of race and sex on physicians\u2019 recommendations for cardiac catheterization. New England Journal of Medicine, 1999. 340(8): p. 618\u201326.","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"1904357_CR62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJM200107193450311","volume":"345","author":"B.R. Edlin","year":"2001","unstructured":"Edlin, B.R., et al., Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med, 2001. 345(3): p. 211\u20135.","journal-title":"N Engl J Med"},{"issue":"1","key":"1904357_CR63","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/jhep.2001.25882","volume":"34","author":"M. Backmund","year":"2001","unstructured":"Backmund, M., et al., Treatment of hepatitis C infection in injection drug users. Hepatology, 2001. 34(1): p. 188\u201393.","journal-title":"Hepatology"},{"key":"1904357_CR64","unstructured":"Sylvestre, D., Sustained virologic response in methadone patients treated for HCV. in 52nd Annual Meeting and Postgraduate Course of the American Association for the Study of Liver Diseases (AASLD). 2001. Dallas, TX."},{"issue":"16","key":"1904357_CR65","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/00002030-200111090-00006","volume":"15","author":"R. Gross","year":"2001","unstructured":"Gross, R., et al., Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. Aids, 2001. 15(16): p. 2109\u201317.","journal-title":"Aids"},{"issue":"10","key":"1904357_CR66","doi-asserted-by":"crossref","first-page":"968","DOI":"10.7326\/0003-4819-134-10-200105150-00011","volume":"134","author":"H. Liu","year":"2001","unstructured":"Liu, H., et al., A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med, 2001. 134(10): p. 968\u201377.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1904357_CR67","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/323201","volume":"33","author":"J.H. Arnsten","year":"2001","unstructured":"Arnsten, J.H., et al., Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis, 2001. 33(8): p. 1417\u201323.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1904357_CR68","doi-asserted-by":"crossref","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"D.L. Paterson","year":"2000","unstructured":"Paterson, D.L., et al., Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med, 2000. 133(1): p. 21\u201330.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1904357_CR69","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/322590","volume":"33","author":"J. McNabb","year":"2001","unstructured":"McNabb, J., et al., Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis, 2001. 33(5): p. 700\u20135.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"1904357_CR70","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00042560-200104150-00005","volume":"26","author":"D.R. Bangsberg","year":"2001","unstructured":"Bangsberg, D.R., et al., Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr, 2001. 26(5): p. 435\u201342.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"1904357_CR71","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1525-1497.1999.05109.x","volume":"14","author":"D.R. Bangsberg","year":"1999","unstructured":"Bangsberg, D.R. and A. Moss, When should we delay highly active antiretroviral therapy? J Gen Intern Med, 1999. 14(7): p. 446\u20138.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"1904357_CR72","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2002.30688","volume":"35","author":"D.M. Forton","year":"2002","unstructured":"Forton, D.M., et al., Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology, 2002. 35(2): p. 433\u20139.","journal-title":"Hepatology"},{"issue":"9","key":"1904357_CR73","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/archinte.1987.00370090055011","volume":"147","author":"P.F. Renault","year":"1987","unstructured":"Renault, P.F., et al., Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med, 1987. 147(9): p. 1577\u201380.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1904357_CR74","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1176\/appi.psy.42.4.365","volume":"42","author":"K. Ademmer","year":"2001","unstructured":"Ademmer, K., et al., Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics, 2001. 42(4): p. 365\u20137.","journal-title":"Psychosomatics"},{"issue":"1","key":"1904357_CR75","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/hep.510290124","volume":"29","author":"H.L. Bonkovsky","year":"1999","unstructured":"Bonkovsky, H.L. and J.M. Woolley, Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology, 1999. 29(1): p. 264\u201370.","journal-title":"Hepatology"},{"issue":"3","key":"1904357_CR76","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1053\/jhep.2002.31311","volume":"35","author":"D. Bernstein","year":"2002","unstructured":"Bernstein, D., et al., Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology, 2002. 35(3): p. 704\u20138.","journal-title":"Hepatology"},{"issue":"4","key":"1904357_CR77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/09540129650125623","volume":"8","author":"M.H. Katz","year":"1996","unstructured":"Katz, M.H., et al., Depression and use of mental health services among HIV-infected men. AIDS Care, 1996, 8(4): p. 433\u201342.","journal-title":"AIDS Care"},{"issue":"5","key":"1904357_CR78","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1525-1497.2000.06219.x","volume":"15","author":"U Sambamoorthi","year":"2000","unstructured":"Sambamoorthi, U, et al., Antidepressant treatment and health services utilization among HIV-infected medicaid patients diagnosed with depression. J Gen Intern Med, 2000. 15(5): p. 311\u201320.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"1904357_CR79","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0376-8716(00)00144-7","volume":"61","author":"M.D. Stein","year":"2001","unstructured":"Stein, M.D., J. Maksad, and J. Clarke, Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend, 2001. 61(3); p. 211\u20135.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"1904357_CR80","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/j.1572-0241.2001.04132.x","volume":"96","author":"S.J. Cotler","year":"2001","unstructured":"Cotler, S.J., et al., Patients\u2019 values for health states associated with hepatitis C and physicians\u2019 estimates of those values. Am J Gastroenterol, 2001. 96(9): p. 2730\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1904357_CR81","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1128\/JCM.38.2.575-577.2000","volume":"38","author":"C.L. Thio","year":"2000","unstructured":"Thio, C.L., et al., Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol, 2000. 38(2): p. 575\u20137.","journal-title":"J Clin Microbiol"},{"issue":"4","key":"1904357_CR82","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00042560-200104010-00008","volume":"26","author":"M. Bonacini","year":"2001","unstructured":"Bonacini, M., H.J. Lin, and F.B. Hollinger, Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr, 2001. 26(4): p. 340\u20134.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1904357_CR83","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.1997.03550010077044","volume":"278","author":"D. Bangsberg","year":"1997","unstructured":"Bangsberg, D., et al., Protease inhibitors in the homeless. Jama, 1997. 278(1): p. 63\u20135.","journal-title":"Jama"},{"issue":"1","key":"1904357_CR84","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2105\/AJPH.91.1.21","volume":"91","author":"D.C. Jarlais Des","year":"2001","unstructured":"Des Jarlais, D.C. and A. Schuchat, Hepatitis C among drug users: deja vu all over again? Am J Public Health, 2001. 91(1): p. 21\u20132.","journal-title":"Am J Public Health"},{"issue":"5","key":"1904357_CR85","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2105\/AJPH.90.5.699","volume":"90","author":"J.D. Bamberger","year":"2000","unstructured":"Bamberger, J.D., et al., Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health, 2000. 90(5): p. 699\u2013701.","journal-title":"Am J Public Health"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1111\/j.1525-1497.2004.30613.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T21:42:27Z","timestamp":1585690947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1111\/j.1525-1497.2004.30613.x"}},"subtitle":["High prevalence but low treatment rates"],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":85,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["1904357"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1497.2004.30613.x","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}